Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 08, 2024 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
July 26, 2024 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
June 14, 2024 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress

Autolus Therapeutics to Present Three Clinical Data Updates on obe-cel at EHA
May 31, 2024 08:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO

Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL
May 17, 2024 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
April 02, 2024 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Autolus Therapeutics announces acceptance of MAA by the EMA for obe-cel for patients with B-ALL
April 01, 2024 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Announces Changes to its Board of Directors

Autolus Therapeutics Announces Changes to its Board of Directors
March 14, 2024 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
February 22, 2024 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics announces publication in Nature Communications

Autolus Therapeutics announces publication in Nature Communications
February 08, 2024 07:00 ET | Source: Autolus Therapeutics plc

Autolus Announces Pricing of Underwritten Offering

Autolus Announces Pricing of Underwritten Offering

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right